Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, With a focus on asparaginase treatment

Hematology Reports

Volumn 6, Issue 3, 2014, Pages 51-57

  Rizzari, Carmelo ^a   Putti, Maria Caterina ^b   Colombini, Antonella ^a   Casagranda, Sara ^a   Ferrari, Giulia Maria ^a   Papayannidis, Cristina ^c   Iacobucci, Ilaria ^c   Abbenante, Maria Chiara ^c   Sartor, Chiara ^c   Martinelli, Giovanni ^c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Clinic of Pediatrics   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acute lymphoblastic leukemia; Adolescent; Asparaginase; Young adult

Indexed keywords

ASPARAGINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANAPHYLAXIS; ARTICLE; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FEVER; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTRANSAMINASEMIA; INFECTION; LEUKEMIA REMISSION; LIVER TOXICITY; NONHUMAN; OVERALL SURVIVAL; PANCREAS DISEASE; PANCREATITIS; POPULATION RESEARCH; PRACTICE GUIDELINE; RISK REDUCTION; SEPSIS; TREATMENT OUTCOME; TREATMENT PLANNING; YOUNG ADULT;

EID: 84907810570     PISSN: 20388322     EISSN: 20388330     Source Type: Journal    
DOI: 10.4081/hr.2014.5554     Document Type: Article

References (52)

1. Mohan SR, Advani AS. Treatment of acute lymphoblastic leukemia in adolescents and young adults. JAYAO 2011;1:19-24.
2. Pui CH, Schrappe M, Ribeiro RC, et al. Childhood and adolescent lymphoid and myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004:118-45.
3. Schafer ES, Hunger S P. Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nat Rev Clin Oncol 2011;8:417-24.
4. Stock W, Douer D, Deangelo DJ, et al. Prevention and management of asparagi-nase/pegasparaginase-associated toxici-ties in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma 2011;52:2237-53.
5. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008;112:1646-54.
6. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Acute lymphoblastic leukemia. 2012. Available from: http://www.nccn.org/pro-fessionals/physician_gls/f_guidelines.asp
7. U.S. National Institutes of Health. Combination chemotherapy in treating young adult patients with acute lym-phoblastic leukemia (LAL1308). Available from: http://clinicaltrials.gov/show/NCT01156883.
8. Pieters R, Hunger S, Boos J, et al. L-asparaginase treatment in acute lym-phoblastic leukemia. Cancer 2011;117:238-49.
9. Müller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998;28:97-113.
10. Iwamoto S, Mihara K, Downing JR, et al. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007;117:1049-57.
11. Schultz KR, Bowman W P, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009;27:5175-81.
12. Testi AM, Piciocchi A, D’angiò R et al. Italian GIMEMA 1308 protocol treatment of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA): intensification of treatment based on the pediatric AIEOP ALL 2000 protocol. Abstract presented at the 19th Congress of the European Hematology Association, Milan, 2014.
13. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-8.
14. Ogawa C, Ohara A, Manabe A, et al. Tokyo Children’s Cancer Study Group (TCCSG) study L99-15. Blood 2005;106:Abstract 878.
15. Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lym-phoblastic leukemia. J Clin Oncol 2005;23:7161-7.
16. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblas-tic lymphoma: a Pediatric Oncology Group study. Leukemia 1999;13:335-42.
17. Rijneveld AW, van der Holt B, Daenen SM, et al. Dutch-Belgian HOVON Cooperative group. Intensified chemotherapy inspired by a pediatric regimen combined with allo-geneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia 2011;25:1697-703.
18. Boissel N, Auclerc M F, Lhéritier V, et al. Should adolescents with acute lym-phoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003;21:774-80.
19. Testi AM, Valsecchi MG, Conter V, et al. Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols. Blood 2004;104: Abstract1954.
20. de Bont JM, Holt B, Dekker AW, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004;18:2032-53.
21. Ram R, Wolach O, Vidal L, et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol 2012;87:472-8.
22. Gokbuget N, Beck J, Brandt K, et al. Significant improvement of outcome in adolescents and young adults (AYAs) aged 15-35 years with acute lymphoblastic leukemia (ALL) with a pediatric derived adult ALL protocol: results of 1529 AYAs in 2 consecutive trials of the German Multicenter Study Group for Adult ALL (GMALL). Presented at 55th ASH Annual Meeting, New Orleans, December 2013.
23. Rytting ME, Thomas DA, O'Brien SM, et al. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer 2014 Jul 17. [Epub ahead of print]
24. Advani AS, Sanford B, Luger S, et al. Frontline treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYAs) using a pediatric regimen is feasible: toxicity results of the prospective US intergroup trial C10403. Presented at 55th ASH Annual Meeting, New Orleans, December 2013.
25. Hough R, Rowntree C, Wade R, et al. Impact of age on toxicity associated with chemotherapy for acute lymphoblastic leukemia (ALL): results from the UK prospective study UKALL2003. Presented at 55th ASH Annual Meeting, New Orleans, December 2013.
26. Plourde PV, Jeha S, Hijiya N, et al. Safety profile of asparaginase Erwinia chrysan-themi in a large compassionate-use trial. Pediatr Blood Cancer 2014;61:1232-8.
27. Breitenbach K, Stock W. Intergroup Trial C10403: a pediatric treatment approach to improve outcomes in adolescents and young adults with acute lymphoblastic leukemia. JAYAO 2011;1:107-8.
28. Stock W. Disparity in outcome of young adults with ALL (response). Blood 2009;113:1862.
29. Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 2009;7:600-6.
30. Hunault-Berger M, Chevallier P, Delain M, et al. GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang). Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lym-phoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica 2008;93:1488-94.
31. Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Oncol 2010:32:554-63.
32. Lowas SR, Marks D, Malempati S. Prevalence of transient hyperglycemia during induction chemotherapy for pedi-atric acute lymphoblastic leukemia. Pediatr Blood Cancer 2009;52:814-8.
33. Sonabend RY, McKay SV, Okcu MF, et al. Hyperglycemia during induction therapy is associated with increased infectious complications in childhood acute lymphocytic leukemia. Pediatr Blood Cancer 2008;51:387-92.
34. Advani A, Earl M, Douer D, et al. Toxicities of intravenous (IV) pegasparaginase (ONCASPAR) in adults with acute lym-phoblastic leukemia (ALL). Blood 2007;110:Abstract 2811.
35. Sonabend RY, McKay SV, Okcu MF, et al. Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. J Pediatr 2009;155:73-8.
36. Raja RA, Schmiegelow K, Frandsen TL. Asparaginase-associated pancreatitis in children. Br J Haematol 2012;159:18-27.
37. Knoderer HM, Robarge J, Flockhart DA. Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer 2007;49: 634-9.
38. Bostrom B. Successful management of extreme hypertriglyceridemia from pegas-pargase with omega-3. Pediatr Blood Cancer 2012;59:350.
39. Tong WH, Pieters R, van der Sluis IM. Successful management of extreme hyper-triglyceridemia in a child with acute lym-phoblastic leukemia by temporarily omitting dexamethasone while continuing asparaginase. Pediatr Blood Cancer 2012; 58:317-8.
40. Rizzari C, Conter V, Starý J, et al. Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr Opin Oncol 2013;25:S1-9.
41. Zalewska-Szewczyk B, Andrzejewski W, Mlynarski W, et al. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2007;48:931-6.
42. Zalewska-Szewczyk B, Gach A, Wyka K, et al. The cross-reactivity of anti-asparagi-nase antibodies against different L-asparaginase preparations. Clin Exp Med 2009;9:113-6.
43. Salzer WL, Asselin B, Supko JG, et al. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood 2013;122:507-14.
44. Asselin BL. The right dose for the right patient. Blood 2012;119:1617-8.
45. Kawedia JD, Liu C, Pei D, et al. Dexamethasone exposure and asparagi-nase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 2012;11: 1658-64.
46. Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed ALL. Blood 2007;109:2744-50.
47. Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in paedi-atric and adult patients with acute lym-phoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haem 2011;152:452-9.
48. Mitchell L, Lambers M, Flege S, et al. Validation of a predictive model for identifying an increased risk for thromboem-bolism in children with acute lymphoblas-tic leukemia: results of a multicenter cohort study. Blood 2010;115:4999-5004.
49. Putti MC, Randi ML. Thrombotic complications in children with haematologic malignancies. Thromb Res 2010;125:S151-4.
50. Santoro N, Colombini A, Silvestri D, et al. Screening for coagulopathy and identification of children with acute lymphoblas-tic leukemia at a higher risk of symptomatic venous thrombosis: an AIEOP experience. J Pediatr Hematol Oncol 2013;35: 348-55.
51. Mitchell LM. Andrew K. Hanna T, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia: results of the PARKAA study. Thromb Haemost 2003;90:235-44.
52. Qureshi A, Mitchell C, Richards S, et al. Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparagi-nase is feasible and safe. Br J Haematol 2010;149:410-3.